Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths in the colon in patients with a rare ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

It has been about a month since the last earnings report for Recursion Pharmaceuticals (RXRX). Shares have added about 6.5% in that time frame, outperforming the S&P 500. But investors have to be ...

We use algorithms every day for things like image searches, predictive text, and securing sensitive data. Algorithms show up all over nature, too, in places like your immune system and schools of fish ...

Alexandra Twin has 15+ years of experience as an editor and writer, covering financial news for public and private companies. David Kindness is a Certified Public Accountant (CPA) and an expert in the ...